Executive Summary: Dr. Reddy’s Laboratories (DRL) Q1 Update

$DRREDDY Market Reaction: Dr. Reddy’s Laboratories equity corrected sharply, falling up to 7% domestically while its US ADRs dropped 10%, following a weaker-than-expected Q1 financial performance driven by US generic deceleration and a product-specific API provision. Key Operational & Financial Drivers US Business Contraction: North American revenue declined 35% YoY to ₹2,204.8 Cr (27% of topline), impacted by lower generic Revlimid sales against a elevated previous-year base. Semaglutide Quality Provision: Profitability was hit by a ₹240 Cr provision linked to out-of-specification API batches. Management confirmed root-cause investigations are active, with no additional provisions expected. Domestic Market Resilience: The India branded segment outperformed street expectations, registering 17% YoY growth (vs. 13–14% estimated). Wall Street Consensus & Brokerage Views The analyst consensus leans distinctly cautious (16 Buy, 10 Hold, 15 Sell out of 41 covering firms): Motilal Oswal (Neutral | Target: ₹1,125): Reduced target price; anticipates earnings contraction in FY27 followed by recovery from FY28 onward. CLSA (Hold | Target: ₹1,240): Cut revenue/margin outlook, modeling a temporary volume loss of 3–4 million Semaglutide pens prior to target normalization in November. JPMorgan (Underweight | Target: ₹1,100): Cites persistent core margin weakness and considers the base business rich at ~30–32x FY27/28 EPS without key execution catalysts. Jefferies (Underperform | Target: ₹1,040): Reduced FY27–29 EPS estimates by 1–15% on timeline risks surrounding Canada Semaglutide launches and b-Abatacept uptake. Policy & Macroeconomic Risks US Trade Tariff Headwinds: Regarding proposals for escalating generic tariffs (100% by Aug 2028, 200% by Aug 2029), management noted that shifting manufacturing to the US is impractical and will await formal government policy guidelines.